Skip to content

Efficacy and predictors of bilateral dentate nucleus deep brain stimulation (DN-DBS) for post-stroke limb motor impairment: a prospective single-arm pilot interventional study

Efficacy and predictors of bilateral dentate nucleus deep brain stimulation (DN-DBS) for post-stroke limb motor impairment: a prospective single-arm, assessor-blinded endpoint pilot study - DN-DBS PSMI-IIT

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121668
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke limb motor impairment (chronic hemiparesis)

Interventions

Single arm:All participants undergo implantation of bilateral dentate nucleus DBS leads and an implantable pulse generator (IPG). Initial programming is performed about 4 weeks postoperatively. Contra

Sponsors

Beijing Chao-Yang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Imaging confirms unilateral ischemic or hemorrhagic stroke, with a duration of >=6 months and <=10 years since onset, and the condition has been relatively stable for the past month; 2. Age 18–80 years; 3. Unilateral hemiplegia as the main deficit, baseline FMA total score 10–50 points; 4. mRS <=3, no severe aphasia or serious cognitive impairment, able to cooperate with assessment and follow-up; 5. MRI shows no extensive cerebellar/brainstem damage; DTI indicates DRTT not completely severed; 6. Able to complete at least 6 months of follow-up and complete rehabilitation and examinations as required; 7. Subject or legally authorized representative signs informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe swallowing disorder or repeated aspiration/inhalation pneumonia; 2. Extensive bilateral cerebellar lesions, or the dentate nucleus/superior cerebellar peduncle/DRTT directly damaged by the lesion; 3. Surgical/anesthesia contraindications (severe cardiopulmonary insufficiency, uncontrolled hypertension, coagulation disorders, etc.); 4. Uncontrolled psychiatric disorders or severe cognitive impairment; 5. Pregnancy/lactation or planning pregnancy during the study period; 6. Other active implanted devices that may interfere with DBS and cannot ensure compatibility; 7. Repeated generalized seizures in the past 6 months or combined with other severe neurological diseases; 8. Severe internal medical comorbidities (active tumor, severe liver or renal failure, etc.); 9. Currently or recently participating in other clinical trials that may interfere with results; 10. Other conditions deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Change in total Fugl–Meyer Assessment motor score (?FMA);

Secondary

MeasureTime frame
Modified Ashworth Scale (MAS) score for spasticity/muscle tone (upper and lower limbs);FMA domain/subscores (UE/LE; proximal/distal; coordination/balance);Toronto Rehabilitation Institute Hand Function Test (TRI-HFT) score;Hospital Anxiety and Depression Scale (HADS) total and subscale scores (HADS-A/HADS-D);Visual Analog Scale (VAS) score for pain/discomfort (0–10);Short Form-36 Health Survey (SF-36) domain scores;

Countries

China

Contacts

Public ContactChangqing Liu

Beijing Chao-Yang Hospital, Capital Medical University

liuchangqing409@163.com+86 151 0106 4296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026